((自动化翻译由路透提供,请见免责声明 ))
12月11日 - ** 制药商MannKind 股价盘前上涨2.1%至6.81美元
** MNKD和合作伙伴Cipla 称,印度中央药品标准控制组织(CDSCO) 已批准 (link) MNKD的胰岛素吸入粉Afrezza
** 这两家公司表示,印度是全球糖尿病发病率第二高的国家
** MNKD预计在2025年底前向CIPL交付产品
** 根据协议,CIPL负责获得在印度分销Afrezza的监管批准以及市场营销和销售活动,而MNKD负责供应Afrezza。
** 截至上次收盘,MNKD 年累计上涨 83.2
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.